The
latest market report published by Credence Research, Inc. “Pneumococcal
Vaccines Market By Vaccine Type (Pneumococcal Conjugate Vaccine,
Pneumococcal Polysaccharide Vaccine), By Product Type (10-Valent PCV, 13-valent
PCV, 23-valent PPSV) - Growth, Future Prospects & Competitive Analysis,
2018 – 2026,” the global pneumococcal vaccines market was valued at
US$ 7,108.7 Mn in 2017 expanding at a CAGR of 5.1% from 2018 to 2026.
Market
Insights
World
Health Organization and U.S. Centers for Disease Control and Prevention (CDC)
has recommended pneumococcal vaccination for all adults above age 65 and
children below 2 years of age. Pneumococcal vaccine may or may not protect
completely against pneumonia, however, it significantly reduces the risk of
invasive pneumococcal diseases. Strong support by local government and private
health organizations such as UNICEF and WHO have driven the demand for
pneumococcal vaccines market. For instance, GAVI, a private and public alliance
have contributed US$ 1.5 billion to the Advanced Market Commitment (AMC) for
pneumococcal vaccines.
Browse the full report at https://www.credenceresearch.com/report/pneumococcal-vaccines-market
GAVI
has helped 60 countries to incorporate pneumococcal vaccines in their routine
programs and immunized more than 143 million children globally in 2017.
Moreover, Gavi has committed US$ 4 billion for pneumococcal vaccine by the
2021. Moreover, growing incidences of pneumococcal diseases worldwide is the
driving factor for the growing demand for pneumococcal vaccines. Pneumonia is
the leading reason for death in children accounting for more than 25% of deaths
of children below age of 5. Growing burden of antibiotic resistance is one of
the major challenges faced by the market.
In
terms of vaccine type, pneumococcal conjugate vaccines (PCV) held the largest
share in the global pneumococcal market owing to more number of PCV products
present in the market i.e. PCV10 and PCV 13. Moreover, on-going clinical trials
of PCV15 and PCV20 by Merck & Co., Inc. and Pfizer, Inc. respectively will
further drive the growth of PCV market during the forecast period. The
pneumococcal polysaccharide vaccine (PPSV) market is projected to grow at
steady rate during the forecast period. In terms of geography, North America
held the largest share in the global pneumococcal vaccines market in 2017.
Increasing government funding and awareness programs in the region is fueling
the market. For instance, pneumococcal conjugate vaccine (PCV) has been
introduced in the routine immunization program to curb the burden of
pneumococcus diseases. Europe holds a significant share in the market due to
efficient vaccination programs in countries such as Italy, Netherlands, United
Kingdom and other countries. Asia Pacific is expected to grow at fastest rate
during the forecast period owing to high incidences of pneumococcal diseases.
High investment and partnerships by pharmaceutical companies will further drive
the market. For instance, in 2017 Pfizer was granted patent protection for
company’s PCV in India. The key players operating in the market include Pfizer,
Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
Key
Market Movements:
- Growing
burden of pneumococcal diseases worldwide and growing awareness regarding
the same
- Increasing
government funding and introduction of effective vaccination programs to
tackle the disease burden
- High demand
for pneumococcal vaccines in developing nations to drive the market
- Strong
support by WHO, UNICEF, GAVI and other private and public organization to
fuel market growth
Download Free PDF
Sample Request: https://www.credenceresearch.com/sample-request/59482
Table of Content
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Pneumococcal Vaccines Market Portraiture
2.2. Global Pneumococcal Vaccines Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global Pneumococcal Vaccines Market, by Product Type, 2017 (US$ Mn)
2.4. Global Pneumococcal Vaccines Market, by Geography, 2017 (US$ Mn)
2.1. Global Pneumococcal Vaccines Market Portraiture
2.2. Global Pneumococcal Vaccines Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global Pneumococcal Vaccines Market, by Product Type, 2017 (US$ Mn)
2.4. Global Pneumococcal Vaccines Market, by Geography, 2017 (US$ Mn)
Chapter 3. Pneumococcal Vaccines: Market Dynamics and
Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pneumococcal Vaccines Market, by Key Players, 2017
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pneumococcal Vaccines Market, by Key Players, 2017
Chapter 4. Global Pneumococcal Vaccines Market, by
Vaccine Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Pneumococcal Conjugate Vaccine
4.3. Pneumococcal Polysaccharide Vaccine
4.1. Overview
4.2. Pneumococcal Conjugate Vaccine
4.3. Pneumococcal Polysaccharide Vaccine
Chapter 5. Global Pneumococcal Vaccines Market, by
Product Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. 10-valent PCV
5.3. 13-valent PCV
5.4. 23-valent PPSV
5.5. Pipeline Analysis
5.5.1. Phase III Analysis
5.5.1.1. 15-valent PCV
5.5.1.2. 20-valent PCV
5.5.2. Tabular Representation of Phase I and Phase II Vaccines
5.1. Overview
5.2. 10-valent PCV
5.3. 13-valent PCV
5.4. 23-valent PPSV
5.5. Pipeline Analysis
5.5.1. Phase III Analysis
5.5.1.1. 15-valent PCV
5.5.1.2. 20-valent PCV
5.5.2. Tabular Representation of Phase I and Phase II Vaccines
Chapter 6. Global Pneumococcal Vaccines Market, by
Geography, 2016 – 2026 (US$ Mn)
6.1. North America Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.1.1. North America Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.1.2. North America Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.1.3. North America Pneumococcal Vaccines Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.2.1. Europe Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.2.2. Europe Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.2.3. Europe Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.4.1. Latin America Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Pneumococcal Vaccines Market, 2016 – 2026
6.5.1. Middle East & Africa Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Pneumococcal Vaccines Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa
6.1. North America Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.1.1. North America Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.1.2. North America Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.1.3. North America Pneumococcal Vaccines Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.2.1. Europe Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.2.2. Europe Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.2.3. Europe Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Pneumococcal Vaccines Market Analysis, 2016 – 2026
6.4.1. Latin America Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Pneumococcal Vaccines Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Pneumococcal Vaccines Market, 2016 – 2026
6.5.1. Middle East & Africa Pneumococcal Vaccines Market, by Vaccine Type, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa Pneumococcal Vaccines Market, by Product Type, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Pneumococcal Vaccines Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa
Chapter 7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. GlaxoSmithKline PLC
7.3. Merck & Co., Inc.
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. GlaxoSmithKline PLC
7.3. Merck & Co., Inc.
Do Enquiry before
Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59482
About Us
Credence Research is a worldwide market research and
counseling firm that serves driving organizations, governments, non legislative
associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most
imperative objectives. Over almost a century, we've manufactured a firm
extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll-Free (US/CANADA) Ph.: +1-800-361-8290
No comments:
Post a Comment